表紙
市場調查報告書

表觀遺傳學的全球市場:成長,趨勢,及預測(2019年∼2024年)

Epigenetics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 629165
出版日期 內容資訊 英文 129 Pages
商品交期: 2-3個工作天內
價格
表觀遺傳學的全球市場:成長,趨勢,及預測(2019年∼2024年) Epigenetics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年12月01日內容資訊: 英文 129 Pages
簡介

本報告提供全球表觀遺傳學市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,套件·試劑·酵素·設備·用途·技術·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
    • 癌症發病率及盛行率的增加
    • 用於醫療研發的資金增加
    • 在非腫瘤疾病中表觀遺傳用途的增加
  • 阻礙因素
    • 設備的成本上升
    • 缺乏熟練的研究人員
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各套件
    • 亞硫酸氫鹽轉換套件
    • ChIP序列套件
    • RNA序列套件
    • 全基因放大套件
    • 5-HMC及的5-MC分析套件
    • 其他
  • 各試劑
    • 抗體
    • 緩衝
    • 組蛋白
    • 磁珠
    • 底層塗料
    • 其他
  • 各酵素
    • DNA修飾酵素
    • 蛋白質修飾酵素
    • RNA修飾酵素
  • 各設備
    • 質譜儀
    • 聲波發生器
    • 新一代定序
    • 其他
  • 各用途
    • 腫瘤學
    • 非腫瘤學
    • 發生生物學
    • 其他
  • 各技術
    • DNA甲基化
    • 組蛋白甲基化
    • 組蛋白乙醯化
    • 大型非編碼RNA
    • 微型核糖核酸修飾
    • 染色絲結構
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abcam PLC
    • Active Motiff
    • Diagenode Inc
    • Illumina Inc
    • Merck & Co., Inc
    • Qiagen NV
    • Sigma Aldrich Corporation
    • Thermo Fisher Scientific
    • Zymo Research Corporation
    • F. Hoffmann-La Roche Ltd

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54639

Market Overview

Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer Society, estimated in 2016, that there were 1,685,210 new cancer cases and about 595,690 deaths due to cancer, in the United States. The National Cancer Institute reported that more than 60% of the world's new cancer cases occur in Africa, Asia, and Central and South America. About 70% of the worldwide deaths due to cancer occur in these regions.

According to the WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer-related policies. This worldwide and extensive threat of cancer remains a major driver for the development of new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.

Cancer resistance to treatment is a major obstacle. However, epigenetic drugs, on their own or in combination with other drugs, can be a viable alternative. The epigenetic drug used in the laboratory study stops the ability of cancer cells to hide from the immune system and makes the tumor vulnerable. So, increasing prevalence of cancer will augment the growth of the epigenetics market.

Scope of the Report

As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome in terms of functionality, which do not involve a change in the nucleotide sequence. The DNA methylation or histone modification is a type of mechanism that causes epigenetic changes.

Key Market Trends

By Technology Segment, DNA methylation is Expected to Hold Largest Share Over the forecast period

DNA methylation dominated the global epigenetics market as it is covalent addition of a methyl group in cytosine ring, which leads to inhibition of transcription. Sensitive bisulfite modification followed by PCR is called methylation sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS are also useful for DNA methylation. Advancements in technologies are increasingly enabling assessment of locus-specific DNA methylation on a genome wide scale.

North America Region Holds the Largest Market Share of Epigenetics Market

North America dominates the epigenetics market, owing to rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in the research and development. With increasing investments being made in the R&D of products by industries, an increase in the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines are produced industrially. In recent years, biopharmaceutical sales have reached 30% of all new pharmaceutical sales in the country. The United States accounts for the world's largest expenditure on healthcare research. All these factors will augment the growth of the studied market.

Competitive Landscape

The market competition is set to intensify as several key players are focusing on the expansion of their epigenetics portfolio through acquisition and collaboration with companies. The epigenetics market is expected to open up several opportunities for new players as well as currently established market leaders.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence and Prevalence of Cancer
    • 4.2.2 Increasing Funding for R&D in Healthcare
    • 4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
  • 4.3 Market Restraints
    • 4.3.1 Rising Costs of Instruments
    • 4.3.2 Dearth of Skilled Researchers
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Kit
    • 5.1.1 Bisulfite Conversion Kit
    • 5.1.2 Chip-seq Kit
    • 5.1.3 RNA Sequencing Kit
    • 5.1.4 Whole Genome Amplification Kit
    • 5.1.5 5-HMC and 5-MC Analysis Kit
    • 5.1.6 Other Kits
  • 5.2 By Reagent
    • 5.2.1 Antibody
    • 5.2.2 Buffer
    • 5.2.3 Histone
    • 5.2.4 Magnetic Bead
    • 5.2.5 Primer
    • 5.2.6 Other Reagents
  • 5.3 By Enzyme
    • 5.3.1 DNA Modifying Enzyme
    • 5.3.2 Protein Modifying Enzyme
    • 5.3.3 RNA Modifying Enzyme
  • 5.4 By Instrument
    • 5.4.1 Mass Spectrometer
    • 5.4.2 Sonicator
    • 5.4.3 Next-generation Sequencer
    • 5.4.4 Other Instruments
  • 5.5 By Application
    • 5.5.1 Oncology
    • 5.5.2 Non-oncology
      • 5.5.2.1 Inflammatory Diseases
      • 5.5.2.2 Metabolic Diseases
      • 5.5.2.3 Infectious Diseases
      • 5.5.2.4 Cardiovascular Diseases
      • 5.5.2.5 Other Non-oncology Applications
    • 5.5.3 Developmental Biology
    • 5.5.4 Other Research Areas
  • 5.6 By Technology
    • 5.6.1 DNA Methylation
    • 5.6.2 Histone Methylation
    • 5.6.3 Histone Acetylation
    • 5.6.4 Large Noncoding RNA
    • 5.6.5 MicroRNA Modification
    • 5.6.6 Chromatin Structures
  • 5.7 Geography
    • 5.7.1 North America
      • 5.7.1.1 US
      • 5.7.1.2 Canada
      • 5.7.1.3 Mexico
    • 5.7.2 Europe
      • 5.7.2.1 Germany
      • 5.7.2.2 UK
      • 5.7.2.3 France
      • 5.7.2.4 Italy
      • 5.7.2.5 Spain
      • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia Pacific
      • 5.7.3.1 China
      • 5.7.3.2 Japan
      • 5.7.3.3 India
      • 5.7.3.4 Australia
      • 5.7.3.5 South Korea
      • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East and Africa
      • 5.7.4.1 GCC
      • 5.7.4.2 South Africa
      • 5.7.4.3 Rest of Middle East and Africa
    • 5.7.5 South America
      • 5.7.5.1 Brazil
      • 5.7.5.2 Argentina
      • 5.7.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abcam PLC
    • 6.1.2 Active Motiff
    • 6.1.3 Diagenode Inc
    • 6.1.4 Illumina Inc
    • 6.1.5 Merck & Co., Inc
    • 6.1.6 Qiagen NV
    • 6.1.7 Sigma Aldrich Corporation
    • 6.1.8 Thermo Fisher Scientific
    • 6.1.9 Zymo Research Corporation
    • 6.1.10 F. Hoffmann-La Roche Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS